REG - Hikma Pharmaceutical - Total Voting Rights

Hikma PharmaceuticalsAnnouncement

03/08/2020 14:30

RNS Number : 9718U
  
Hikma Pharmaceuticals Plc
  
03 August 2020
  
 

 
Hikma Pharmaceuticals PLC
(the Company) 
Total Voting Rights and Capital
 
LONDON, 3 August 2020 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that,  in accordance with the Disclosure Guidance and Transparency Rules ('the Rules'), we notify the market of the following:
 
As at 31 July 2020, the issued share capital of the Company comprised of 230,466,752 ordinary shares with voting rights. This figure excludes 12,833,433 Shares held in treasury.
  
The figure of 230,466,752 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.
 
 
 
 
- ENDS -
 
Enquiries
 




Hikma Pharmaceuticals PLC
 


 




Peter Speirs
Company Secretary
 


+44 20 7399 2760
 




 


 


 




 
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TVREADPDEASEEFA